IAN READ, the chief executive of Pfizer, is not a man easily rebuffed. His attempt to woo AstraZeneca, a British drugs firm, included politesse—appearances before Parliament, web videos on Pfizer’s strategy—and, more importantly, a sweetened offer on May 18th worth around £70 billion ($120 billion). However, AstraZeneca’s board has rejected the bid and, as we went to press, it seemed dead in the water.
{iframe}http://www.economist.com/news/business/21602689-why-row-over-giant-drug-company-takeovers-misses-point-pharmed-out{/iframe}